Mesoblast (ASX:MSB) secured a regenerative advanced therapy designation from the US Food and Drug Administration for Revascor-branded rexlemestrocel-L cell therapy for pediatric patients with congenital heart disease, according to a Thursday filing with the Australian bourse.
The status was granted following results from a clinical trial investigating the use of the therapy in children with hypoplastic left heart syndrome (HLHS), the filing said.
Revascor was previously granted by the health regulator with both a rare pediatric disease designation and an orphan drug designation for pediatric patients with HLHS, the filing added.
The company's shares tumbled almost 8% in recent Thursday trade but earlier hit their highest since August 2021.
Price (AUD): $1.62, Change: $-0.14, Percent Change: -7.95%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。